Closing in on our next major milestone
Closer to clinical trials We are now closing in on our next major milestone: initiating clinical trials with the stem cell product XSTEM. Many pieces of the puzzle have fallen into place for us to get this far, each of which reflects a great deal of hard, goal-oriented work by our team. Some of […]
Newsletter December 2020
Dear shareholders, It has been an unusual year that was dominated by COVID-19 and we have had to adapt our business to the prevailing pandemic. Thanks to the fantastic effort by our team and strict procedures, we have nonetheless been able continue our operations safely and can now say that 2020 was a very successful […]
Newsletter November 2020
Dear shareholders, Xintela is targeting several important milestones in the remainder of 2020 and 2021, which are the result of years of strategic, goal-oriented efforts in stem-cell and cancer treatment projects. In the summary below, I present updates on the status of Xintela’s projects and of the company’s strategy and future milestones, in both the […]
Newsletter December 2019
Newsletter December 2019 Progress on several fronts during the year 2019 was an intensive and successful year for our projects in stem cell therapy and oncology and it is now exhilarating to look back over all the progress made by the company. The following newsletter summarises how Xintela’s operations have changed during the year and […]
Newsletter July 2019
This newsletter was released in Swedish on the 12th of July The beautiful summer has also arrived at Xintela and our employees are now looking forward to a well-deserved break. The summer also gives me more time to think about how Xintela’s various projects have moved forward since the start and about everything exciting […]
Steady progress and Xintela is growing
Projects making steady progress and Xintela is growing Projects in both regenerative medicine and oncology are making progress and developing very positively, which has required us to hire more personnel. We are now 18 employees and five consultants in the company, and we expect to recruit additional personal before long. As a result, we have […]
A successful year
Xintela had a very eventful year with success regarding both projects and financing. The following presentation summarises the status of Xintela’s various activities and overall plans for the coming year. Through a directed issue of approximately MSEK 50 to the German orthopaedic company Bauerfeind AG, we achieved financial stability and a long-term owner with a […]
Xintela at partnering conferences
Xintela has worked intensively to connect the company with potential partners and international investors. Thomas Areschoug, Business Development Manager at Xintela, tells more about the conferences that the company attended during the autumn. Xintela participated in a number of partnering conferences during the autumn. First of all, why it is so important for Xintela to […]
Newsletter no 2 2018
It is both pleasing and stimulating to look back on the intensive past six months. Our projects have shown great progress and Xintela has made significant advances. One key focus was the completion of our own GMP facility to produce stem cells for clinical trials. We opened the facility, which is located at Medicon Village […]
Newsletter no 1 2018
In 2017, Xintela took numerous steps that enabled the company to grow into a prominent player in the field of regenerative medicine, including building its own GMP facility for stem cell production. We also broadened our product options within the cancer project by licensing human antibodies that bind to our integrin markers. Construction of our […]
